| --- | --- | --- | --- | |---------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Bringing Agreements | | | | | to Life | | | | | | | | | | Q2 FY25 | | | | | | | | | | | | | | | | | | | Safe Harbor This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information c ...

FISCAL 2Q'25 planet. UPDATE September 5, 2024 OLYMPIC RINGS, EIFFEL TOWER, PARIS, FRANCE August 11, 2024 • SkySat Disclaimers All references to "Planet" or the "Company" in this presentation are references to Planet Labs PBC (NYSE: PL). Forward-looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to fu ...

业务发展 - Alcoa于2024年8月1日完成对Alumina Limited的收购，加强了作为世界最大的铝土矿和氧化铝生产商之一的地位[6] - Alcoa的业务部门在2023年处于铝土矿和氧化铝成本曲线的第一四分位，2023年处于铝成本曲线的第二四分位[9] - Alcoa计划通过长期技术项目，如“未来铝厂”项目和ELYSIS惰性阳极技术，实现减少排放和提高回收利用率的目标[28] 市场趋势 - 全球铝市场在2024年至2033年预计总需求增长为11.3百万吨，主要受到低碳趋势驱动[13] - 中国限制供应并设定碳排放目标，导致全球铝供应增长主要由中国以外地区主导[14] - 中国市场铝价上涨，反映市场动态[60] 财务表现 - Alcoa的财报显示，第二季度收入、每股收益和调整后的EBITDA均环比增长[41] - Alcoa的调整后EBITDA（不含特殊项目）在第二季度较上季度增长了193百万美元[44] - Alcoa公司的总收入为29.06亿美元，调整后的EBITDA为3.25亿美元[85] 财务状况 - Alcoa的现金流情况良好，第二季度现金结余为14亿美元，工作资本周转天数降至41天[51] - Alcoa公司的自由现金流为123百万美元[114] - Alcoa公司的净债务为1,308百万美元[115]

CUI P Positioning for the Future Culp Restructuring Plan – September 2024 1 Forward Looking Statements 2 This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934). Such statements are inherently subject to risks and uncertainties that may cause actual events and results to differ materially from ...

业绩总结 - Q3 2024总资产达到45.2亿美元，贷款组合达到40.5亿美元，同比增长11%[6] - Q3 2024总收入同比增长1%，净收入同比增长3%[7] - Q3 2024每股收益同比增长5%[7] - Q3 2024资产负债表显示总资产13%增长，贷款组合11%增长[11] - Q3 2024净利润同比下降3%[13] 新产品和新技术研发 - Point-of-Sale Receivable Purchase Program为Point-of-Sale金融公司提供创新、独特和高效的数字资金解决方案[27] 市场扩张和并购 - 公司在核心数字银行业务中实现了显著的运营杠杆[28] 未来展望 - 公司的下一个里程碑是总资产超过50亿美元，非利息支出超过20%[30]

Methode Electronics, Inc. Earnings Presentation First Quarter Fiscal 2025 September 5, 2024 2 Forward-Looking Statements This presentation forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, when made, our current views with respect to current events and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to our operations and business environment, which may cause our actual resul ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | FINANCIAL RESULTS | | | | | | | FY25 2Q | | | | | | | SUPPLEMENTAL FINANCIAL PRESENTATION September 5, 2024 | | | | | | | SAIC. | | | | | | Forward Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "m ...

产品进展 - AFM24 + Atezolizumab在NSCLC EGFRmut扩展队列中显示出23.5%的ORR，47.0%的SD，70.6%的DCR[11] - LuminICE-203研究中，Acimtamig+AlloNK治疗复发/难治霍奇金淋巴瘤患者，显示出83.3%的ORR，50.0%的CRR[23] - AFM28-101在复发/难治急性髓系白血病患者中显示出无剂量限制毒性，预测有效剂量为200-300mg[31] - AFM28-101的CD123双特异性细胞结合剂在复发/难治急性髓系白血病中展现出良好的临床信号[34] - AFM28单药数据在AFM28-101中证实了对r/r AML患者早期疗效的迹象，为进一步开发组合治疗提供了验证[35] - 在250毫克剂量下接受治疗的一个患者达到完全缓解（CR），并在6个周期中持续从AFM28治疗中受益[35] - 在最高剂量水平（300毫克AFM28）下，6名患者中有3名（50%）达到CR或CRi[35] 市场需求 - R/R AML患者中60%是初次难治或在初始治疗后1年内复发，需要新的更安全和有效的选择[37] - 在7MM*中有超过14,000名AML患者在第二线治疗后进展，可选项有限[38] 业务展望 - 其他AML靶向疗法的进一步发展，包括与冷冻保存的现成NK细胞产品的组合[39] - 选择的资产在临床中取得进展，显示在复发/难治患者中具有潜力[44] - 三项正在进行的ICE®研究证实了先天免疫系统在抗击癌症中的潜力[46]

Secureworks Investor Presentation l September 2024 | --- | --- | |-------------------|-------| | | | | Operating Metrics | | | | | | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Our Mission To secure human progress by outpacing and outmaneuvering the adversary | | | | | | | | | | | | | | | Taegis Driving Profitability and Growth ~98% MITRE ATT&CK® Framework Coverage >60 Countries Leading Provider of Award- ...

HARMONY" FY24 ANNUAL RESULTS Peter Steenkamp, CEO 5 September 2024 © Harmony JSE ticker code HAR NYSE ticker code HMY MINING WITH PURPOSE 2 © Harmony PRIVATE SECURITIES LITIGATION REFORM ACT SAFE HARBOUR STATEMENT AND DISCLAIMER FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the safe harbour provided by Section 21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), with respect to our financial conditi ...